We've seen some of the COVID beneficiary stocks pan out quite well lately. Here is another that may have found bottom. MACD nicely improving.
Watch for it to work through $110 - $114.
First target is the $122 gap fill.
We've seen some of the COVID beneficiary stocks pan out quite well lately. Here is another that may have found bottom. MACD nicely improving.
Watch for it to work through $110 - $114.
First target is the $122 gap fill.